This is a working overview of WADA, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-17. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
While this process depletes glutathione initially, it paradoxically stimulates increased glutathione synthesis. The compound's anti-proliferative effects appear particularly pronounced in cancer cells with compromised mitochondrial function, suggesting a relationship between mitochondrial fitness and therapeutic efficacy.
=== Cuban Thaw and attempts to repair relationship === In 2011, Lazaro Cuesta Valdes was elected as the Grand Commander of the Supreme Council of Cuba. After his election, the Supreme Council created a Facebook page, launched an updated webpage, and launched the first International Conference on Freemasonry and Integration to Current Society. Between 2012 and 2014, Grand Commander Cuesta Valdes travelled around the world, first to Rome, and then to visit the Supreme Councils of the United States' Southern Jurisdiction and Northern Jurisdiction, in Ohio and Washington, D.C. Informally, he also met with leaders of the Cuban exile Freemasonry community in Miami to strengthen relations with the United States. In October 2013, the Supreme Council of Cuba held an open meeting and invited Cuban Masons living anywhere to Havana to discuss the fractured state of Cuban Freemasonry. Grand Master Gutierrez Torres attended and drafted Official Message No. 6 after discussions with members of the diaspora. In April 2014, while still in prison, Alan Gross launched a hunger strike to protest his treatment by both Cuba and the United States. When the Associated Press leaked the ZunZuneo program documents to the public, Senator Patrick Leahy called it: "Dumb, dumb, dumb." Leahy then led the Senate committee review of the debacle. On December 17, 2014, Alan Gross was released from Cuban prison in exchange for three members of the Cuban Five, who had been detained in the United States and charged with espionage. On December 10, 2016, the Lazaro F.
In relation to the significance of the event(s) on career choice, when merging the categories ‘probably chosen career regardless’ with ‘possibly chosen career regardless’, and ‘unlikely chosen career regardless’ with ‘not considered career otherwise’, there is a slight majority in relation to the former. There are no significant differences in relation to demographic factors. In relation to whether one or more psychologically wounding experiences led to the choice of a career as a therapist, there is a significant difference within designation, gender, grouping gender and ethnicity, and, grouping gender and age. There are no significant differences within approach, ethnicity or age. The majority of the wounds were caused by events experienced directly by the respondents (65%) as opposed to indirectly or both. Within demographic factors, the causes of the wounding experiences leading to career choice are not statistically significant. The exact causes of the wounds vary enormously. The main categories are abuse, family life as a child, mental ill-health (own), social, family life as an adult, bereavement, mental ill-health (others), life-threatening, physical ill-health (others), physical ill-health (own), and, other. There are many implications for the future of the therapeutic world, focusing mainly on supervision and training. The largest prevalence study on lived experience within the mental health field by Victor et al.
==== Indications ==== Cannabidiol, available as Epidiolex® in high concentration, is a synthetic non-classical cannabinoid marketed for the treatment of refractory epilepsy in patients with Dravet syndrome (epilepsy condition since infancy), Lennox-Gastaut syndrome (severe epilepsy in children), and tuberous sclerosis (a genetic condition causing the formation of non-cancerous tumours in different body areas) in patients aged 1 or above. A reduction in the frequency seizures (uncontrolled shaking of body due to abnormal brain activity) and a better seizure control are seen among patients.
Sources: en.wikipedia.org
== System components == A typical laboratory FPLC consist of one or two high-precision pumps, a control unit, a column, a detection system and a fraction collector. Although it is possible to operate the system manually, the components are normally linked to a personal computer or, in older units, a microcontroller.
==== Wismut AG ==== The approximately 200,000 uranium miners employed by Wismut AG in the former Soviet occupation zone of East Germany were exposed to very high levels of radiation, particularly between 1946 and 1955, but also in later years. This exposure was caused by the inhalation of radon and its radioactive by-products, which were deposited to a considerable extent in the inhaled dust. Radiation exposure was expressed in the historical unit of working level month (WLM). This unit of measurement was introduced in the 1950s specifically for occupational safety in uranium mines in the U.S. to record radiation exposure resulting from radioactive exposure to radon and its decay products in the air we breathe. Approximately 9000 workers at Wismut AG have been diagnosed with lung cancer.
== Work == During his career, Roderich Süssmuth worked in the field of peptide synthesis, addressing current research questions from both a chemical perspective (natural product synthesis) and a biological perspective, particularly with regard to new classes of active compounds with activity against fungi, bacteria, and viruses. Compounds derived from plant-pathogenic bacteria such as Xanthomonas albilineans play an important role, including albicidin, which is an inhibitor of plant gyrase and also a highly potent antibacterial agent. He elucidated the structure of the antibacterial compound albicidin, investigated its biosynthesis, developed the total synthesis of the peptide, and studied a range of bacterial resistance factors, mostly from plant-associated bacteria. Another example is the recent elucidation of a lipopeptide from Burkholderia sp., which exhibits pronounced activity against plant-pathogenic fungi. Another area of research involves fungal toxins of the death cap mushroom, phalloidin and amanitin, for which total syntheses were developed and, with the ansamer concept, a novel non-classical atropisomerism was described.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.